Showing 3311-3320 of 3506 results for "".
- Neutrogena Sunscreens Awarded NEA Seal of Acceptancehttps://practicaldermatology.com/news/neutrogena-sunscreens-awarded-nea-seal-of-acceptance/2458928/The National Eczema Association (NEA) awarded its Seal of Acceptance to five Neutrogena sunscreens. This recognition is given to product innovations that help improve the quality of life for people with eczema, empowering consumers to make informed eczema purchase decisions. The fol
- Immune Pharmaceuticals Expands Immuno-Dermatology Development Portfolio With Topical Nano-Formulated Cyclosporine Ahttps://practicaldermatology.com/news/immune-pharmaceuticals-expands-immuno-dermatology-development-portfolio-with-topical-nano-formulated-cyclosporine-a/2458932/Immune Pharmaceuticals Inc. entered into a binding Memorandum of Understanding with Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem regarding the worldwide exclusive licensing and development of a topical, biodegradable, nano-capsule formulation of cyclospo
- The American Academy of Dermatology Elects New Officers and Board Membershttps://practicaldermatology.com/news/the-american-academy-of-dermatology-elects-new-officers-and-board-members/2458941/The American Academy of Dermatology (AAD) announced the results of its annual election. The newly elected officers and board members will lead the AAD, which represents more than 19,000 physicians. These officers and board members also will hold the same positions for the American Academy of Derm
- Encore Dermatology, Inc.: A New Specialty Dermatology Company Launcheshttps://practicaldermatology.com/news/encore-dermatology-inc-a-new-specialty-dermatology-company/2458942/Encore Dermatology, Inc. announced has begun to commercialize Hylatopic®, Tetrix™, and BenzEFoam™, three established topical dermatology products acquired from Valeant Pharmaceuticals North America, LLC and certain of its affiliates. Encore Dermatology, Inc. is a privately
- AbbVie Receives FDA Orphan Drug Designation for Humira for the Investigational Treatment of Moderate-to-Severe Hidradenitis Suppurativahttps://practicaldermatology.com/news/abbvie-receives-fda-orphan-drug-designation-for-humira-for-the-investigational-treatment-of-moderate-to-severe-hidradenitis-suppurativa/2458945/AbbVie announced that the FDA has granted Humira® (adalimumab) orphan drug designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (HS) (Hurley Stage II and Hurley Stage III disease), a painful, chronic inflammatory skin disease. AbbVie's su
- Merck's Pembrolizumab Demonstrates Positive Results in Phase III Study for Advanced Melanomahttps://practicaldermatology.com/news/mercks-pembrolizumab-demonstrates-positive-results-in-phase-iii-study-for-advanced-melanoma/2458959/Merck announced results from the randomized, pivotal Phase III study, KEYNOTE-006, in the treatment of unresectable advanced melanoma. In the study, pembrolizumab was statistically superior to ipilimumab for progression-free survival (PFS), overall survival (OS), and overall response rate (ORR).
- Provectus Biopharmaceuticals, Pfizer Receive Patent Allowance for Use of PV-10 in Combination with Systemic Immunotherapy Agents in Treatment of Cancerhttps://practicaldermatology.com/news/provectus-biopharmaceuticals-pfizer-receive-patent-allowance-for-use-of-pv-10-in-combination-with-systemic-immunotherapy-agents-in-treatment-of-cancer/2458962/Provectus Biopharmaceuticals, Inc., a clinical-stage oncology and dermatology biopharmaceutical company, announced today that it has received from the US Patent and Trademark Office a N
- FDA Clears Syneron Candela's PicoWay Picosecond Laser for Treatment of Pigmented Lesionshttps://practicaldermatology.com/news/fda-clears-syneron-candelas-picoway-picosecond-laser-for-treatment-of-pigmented-lesions/2458961/The FDA cleared Syneron Medical Ltd.’s PicoWay® picosecond laser for the treatment of pigmented lesions. The PicoWay picosecond laser previously received FDA clearance for the removal of tattoos in November 2014 and was launched in the US late in the fourth quarter 2014. PicoWay
- Association of Dermatology Administrators and Managers Names Alice Hyman “Practice Manager of the Year”https://practicaldermatology.com/news/association-of-dermatology-administrators-and-managers-names-alice-hyman-practice-manager-of-the-year/2458966/The Association of Dermatology Administrators and Managers (ADAM) named Alice Hyman of Advanced DermCare in Danbury, CT, the recipient of this year’s Practice Manager of the Year award. She was recognized at the 23rd annual ADAM meeting in San Francisco. Ms. Hyma
- Cipher Pharmaceuticals Acquires Innocutishttps://practicaldermatology.com/news/cipher-pharmaceuticals-acquires-innocutis/2458969/Cipher Pharmaceuticals Inc. has acquired Innocutis Holdings LLC, a privately held specialty dermatology company, for US$45.5 million in cash. (All financial references are in U.S. dollars unless otherwise noted.) "This acquisition marks our commercial entry to the U.S. market an